Ownership history in MPM ASSET MANAGEMENT LLC · 9 quarters on record
This page tracks every 13F SEC filing in which MPM ASSET MANAGEMENT LLC reported a position in Adaptimmune Therapeutics plc (ADAP). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q2 | REDUCED | 4,809,677 | -526,038 | -9.9% | 2.66% | $1.15B | — |
| 2025 Q1 | REDUCED | 5,335,715 | -219,746 | -4.0% | 1.51% | $1.1M | — |
| 2024 Q4 | UNCHANGED | 5,555,461 | — | 0% | 2.41% | $3.0M | — |
| 2024 Q3 | UNCHANGED | 5,555,461 | — | 0% | 3.63% | $5.3M | — |
As of 2025 Q4 — sorted by position size